相似文献
1
International consensus definition of disease flare in hidradenitis suppurativa.
Br J Dermatol. 2022 Nov;187(5):785-787. doi: 10.1111/bjd.21647. Epub 2022 Jul 25.
2
Hemoglobin as an indicator of disease activity in severe hidradenitis suppurativa.
Int J Dermatol. 2019 Sep;58(9):1090-1091. doi: 10.1111/ijd.14170. Epub 2018 Aug 10.
3
A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa.
JAMA Dermatol. 2018 Mar 1;154(3):330-335. doi: 10.1001/jamadermatol.2017.5890.
4
Identifying triggers for hidradenitis suppurativa flare: a patient survey.
Br J Dermatol. 2021 Jul;185(1):225-226. doi: 10.1111/bjd.19926. Epub 2021 May 4.
5
Characterizing physical symptoms of flare in hidradenitis suppurativa: a patient survey.
Br J Dermatol. 2021 Jan;184(1):160-162. doi: 10.1111/bjd.19412. Epub 2020 Sep 1.
6
Sepsis-like features in hidradenitis suppurativa flares requiring admission: A retrospective cohort study.
J Am Acad Dermatol. 2024 Jun;90(6):1291-1294. doi: 10.1016/j.jaad.2024.02.022. Epub 2024 Feb 21.
7
Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1.
Australas J Dermatol. 2018 Nov;59(4):267-277. doi: 10.1111/ajd.12770. Epub 2018 Jan 21.
8
Correlation between Depression, Quality of Life and Clinical Severity in Patients with Hidradenitis Suppurativa.
Acta Derm Venereol. 2020 Nov 12;100(18):adv00319. doi: 10.2340/00015555-3647.
9
Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.
Dermatology. 2020;236(1):8-14. doi: 10.1159/000501771. Epub 2019 Sep 5.
10
Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa.
Br J Dermatol. 2020 Jan;182(1):240-242. doi: 10.1111/bjd.18335. Epub 2019 Sep 17.
引用本文的文献
1
Flare-ups: New Insights into the Burden of Pain in Hidradenitis Suppurativa.
Acta Derm Venereol. 2025 Mar 18;105:adv43124. doi: 10.2340/actadv.v105.43124.
2
Factors associated with therapeutic response to adalimumab in hidradenitis suppurativa: evidence from the Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be).
Arch Dermatol Res. 2025 Jan 7;317(1):189. doi: 10.1007/s00403-024-03675-w.
3
Australasian hidradenitis suppurativa management guidelines.
Australas J Dermatol. 2025 Mar;66(2):75-89. doi: 10.1111/ajd.14388. Epub 2024 Nov 22.
4
Improving hidradenitis suppurativa management: consensus statements from physicians and patients' perspectives.
Arch Dermatol Res. 2024 Aug 24;316(8):577. doi: 10.1007/s00403-024-03316-2.
5
Hidradenitis Suppurativa in the SARS-CoV-2 Pandemic: Investigation of Trigger Factors in a Single Center.
J Clin Med. 2024 Jul 12;13(14):4074. doi: 10.3390/jcm13144074.
6
Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.
Front Med (Lausanne). 2024 Jul 8;11:1403455. doi: 10.3389/fmed.2024.1403455. eCollection 2024.
7
Expert Practices in Hidradenitis Suppurativa Flare Management: A Cross-Sectional Survey Study.
Skin Appendage Disord. 2024 Jun;10(3):224-228. doi: 10.1159/000536094. Epub 2024 Jan 24.
8
Retinal Microvascular Alterations in Hidradenitis Suppurativa Patients: A Pilot Study Using Optical Coherence Tomography Angiography.
J Clin Med. 2024 Mar 2;13(5):1464. doi: 10.3390/jcm13051464.
9
Patient practices in hidradenitis suppurativa flare management: a cross-sectional survey study.
Arch Dermatol Res. 2023 Dec 4;316(1):13. doi: 10.1007/s00403-023-02782-4.
10
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
本文引用的文献
1
Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment.
Br J Dermatol. 2021 May;184(5):905-912. doi: 10.1111/bjd.19565. Epub 2020 Dec 30.
2
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.
J Am Acad Dermatol. 2020 Feb;82(2):366-376. doi: 10.1016/j.jaad.2019.06.1301. Epub 2019 Jul 3.
3
Periodic worsening, or flare, in hidradenitis suppurativa: the perspective of people with hidradenitis.
Br J Dermatol. 2020 Jan;182(1):218-219. doi: 10.1111/bjd.18210. Epub 2019 Jul 28.
4
A narrative review of the definition of 'flare' in hidradenitis suppurativa.
Br J Dermatol. 2020 Jan;182(1):24-28. doi: 10.1111/bjd.18035. Epub 2019 Jul 28.
5
Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
Br J Dermatol. 2019 Sep;181(3):483-491. doi: 10.1111/bjd.17716. Epub 2019 Jun 6.
6
Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI).
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S112-7. doi: 10.1002/acr.20623.
7
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.
J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.
Zotero 插件